Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Bullboard - Stock Discussion Forum Spectral Medical Inc T.EDT

Alternate Symbol(s):  EDTXF

Spectral Medical Inc. is a Canada-based late-stage theragnostic company advancing therapeutic options for sepsis and septic shock. The Company develops and commercializes a treatment for septic shock utilizing its Endotoxin Activity Assay (EAA) diagnostic and the Toraymyxin therapeutic (PMX). PMX is a therapeutic hemoperfusion device that removes endotoxin, which can cause sepsis, from the... see more

TSX:EDT - Post Discussion

Spectral Medical Inc > "Altercyte or Overcyte" EDTXF, the "PINK Planter" ......
View:
Post by SouthernTierTom on Jun 09, 2022 9:33am

"Altercyte or Overcyte" EDTXF, the "PINK Planter" ......

With NO price target ?  This sent to me from Canada, *warning - Chilly presentation may require full "DE-frosting" prior to "Bon Appetito'ing" ; - )

How might a solid and honorable Canadien get the US OTC PINK exchange all mixed up with his/her very own top of the table TSE (Toronto stock exchange)?

Anyone have the number for Paradigm?  Eden? ; - )

According to websites here in the US, the OTC PINK exchange is really just a rogue "wild wild west mall exchange" that is near impossible to transact on....apparently analysts DON'T generally go near it.  Our US leadership might be aware of this important detail.  Good AGM fodder to compliment the bench plasma study comparing PMX, Oxiris and the fore-door Sorb XL gem ; - )

Analyst Scott McAuley
Scott McAuley
Paradigm
Main Sector: Unknown
0.6 star
 
 
 
 
 
 
 
 
 
 
0.6
ANALYST PERFORMANCE
Success Rate
27%
3 out of 11 successful ratings
Average Return-15.10%Average Return Per Rating
Analyst Ranking
0.6
0.6 star
 
 
 
 
 
 
 
 
 
 
Scott is ranked #6,991 out of 7,941 analysts
RECENT RATINGS
Company Name Position Price Target Action Date
TSE:OPS
Opsens Inc
Buy
$4
7.20% Upside
Maintained 56 Days ago
EDTXF
Spectral Medical
Buy
--
-4.50%
Maintained 63 Days ago
ZYME
Zymeworks
Buy
$24
-23.73%
Maintained 120 Days ag
Comment by mercedesman on Jun 09, 2022 2:07pm
I guess, even the most gifted (those in the top 90% of all analysts), occassionally do make mistakes.  Like forgetting the main exchange a stock trades on, or what the price target is. What is that 0.6 Analyst ranking mean ?  Does that mean he is rated at 6/10ths of 1 out of 10? I thought it might be the ratio of the current SP to the Anlayst Target Price, but that's .15 (or for ...more  
Comment by hmmmmmmmm on Jun 09, 2022 2:41pm
"Exceeding Expectations" ?  stuck at 34 out of 150 patients enrolled.   Averaging 1 patient enrolled per month or less for the past 2+ years... Are we looking at 116 months to complete the Tigris trial? I guess Management's expectations were very, very low.
Comment by SouthernTierTom on Jun 09, 2022 3:18pm
Where art thou share price target?  Where art thou the "Toronto Stock Exchange" Our most recent comment from our most respected CMO, global leader ( aka global KOL ) was that recent recruitment in the TIGERIS phase 3b confirmatory trial was "BRISK" ... I just wonder why Vicenza on it's glorious 40th birthday would choose the following presentation from a known top ...more  
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities